Τόμος 25 (2007) – Τεύχος 2+3 – Άρθρο 5 – Επιθεώρηση Κλινικής Φαρμακολογίας και Φαρμακοκινητικής-Ελληνική Έκδοση – Volume 25 (2007) – Issue 2+3– Article 5 – Epitheorese Klinikes Farmakologias και Farmakokinetikes-Greek Edition

Σοφία Κωστούδη και Μαρία Μυρωνίδου-Τζουβελέκη

Εργαστήριο Φαρμακολογίας, Ιατρική Σχολή, Αριστοτέλειο Πανεπιστήμιο, Θεσσαλονίκη, Ελλάς

Sofia Kostoudi and Maria Mironidou-Tzou­veleki

Department of Pharmacology, Medical School, Aristotle University, Thessaloniki, Greece

2. Global Initiative for Asthma, Global Strategy for asthma management and prevention, National Institutes of Health, National Heart, Lung and Blood Institute. Pp. 2-9, 28-66, 146-147 (2002)

3. Goldman L., Bennett C.: Cecil Νοσολογία, Φυσιοπαθολογία – Διάγνωση – Θεραπεία. T.1, Άσθμα υπό Drazen J., σελ. 560-9, εκδ. Πασχαλίδης, Αθήνα, 2002

4. Janeway C, Travers P.: Κλινική Ανοσοβιολογία. Το Ανοσολογικό σύστημα στην υγεία και τη νόσο, Αθήνα, Πασχαλίδης, 2002

5. Currie G., Devereux G., Lee D., Ayres J.: Πρόσφατες εξελίξεις στην αντιμετώπιση του άσθματος. BMJ 61: 47-54 (2005)

6. http://www.aihw.gov.au/nhpa/asthma/

7. http://www.duleekpharmacy.com/cms/publish/printer_1.shtml

8. Marketos S.G., Ballas C.N.: Bronchial asthma in the medical literature of Greek antiquity, J. Asthma 19: 263-269 (1982)

9. http://en.wikipedia.org/wiki/Asthma

10. http://www.yourmedicalguide.com/Respiratory-System/Asthma-History.htm

11. http://asthmatrack.com/famous_asthmatics.html

12. http://www.nlm.nih.gov/hmd/breath/Faces_asthma/VIIA4.html

13. http://www.nlm.nih.gov/hmd/breath/Faces_asthma/VIIA12.html

14. http://www.nlm.nih.gov/hmd/breath/Faces_asthma/VIIA13.html

15. http://www.nlm.nih.gov/hmd/breath/Faces_asthma/VIIA17.html

16. Strachan D.P.: The epidemiology of childhood asthma. Allergy 54 (Suppl. 49): 7-11 (1999)

17. http://www.merckmedicus.com/pp/us/hcp/diseasemod­ules/asthma/epidemiology.jsp

18. Björkstén B.: The environmental influence on child­hood asthma. Allergy 54 (Suppl. 49): 17-23 (1999)

19. http://www.healthandenergy.com/asthma_increasing.htm

20. http://www.pamf.org/asthma/overview/triggers.html

21. http://www.aeroallergen.gr/epidimiologia.asp

22. http://www.aeroallergen.gr/infoA3.asp

23. http://www.medceu.com/tests/pediatricasthma.htm

24. http://on.lung.ca/yourlungs/asthmaintro.html

25. http://www.equip.ac.uk/docs/issues/issue5/morbidity.htm

26. Martinez F.D.: Recognizing early asthma. Allergy 54 (Suppl. 49): 24-28 (1999)

27. Björnsdottir U.S., Cypcar D.M: Asthma: an inflam­matory mediator soup. Allergy 54 (Supplement 49): 55-61 (1999)

28. Barnes P.: Asthma, Inflammatory Mechanisms and Therapy. Clinical Vision Ltd, The Old Chapel Harwell, U.K., 1996

29.O’Byrne P., Inman M., Adelroth E.: Reassessing the Th2 cytokine basis of asthma. Trends Pharmacol. Sci. 25: 244-248 (2004)

30. Donnely L., Barnes P.: Acidic mammalian chitinase – a potential target for asthma therapy. Trends Pharmacol. Sci. 25: 509-511 (2004)

31. Holt P., Macaubs C., Prescott S.L., Sly P.D.: Microbial stimulation as an aetiologic factor in atopic disease. Allergy 54 (Supplement 49): 12-16 (1999)

32. http://www.pathology.vcu.edu/education/dental2/lab5.html

33. http://www.divuslabs.com/asthma.htm

34. http://focus.hms.harvard.edu/2001/Jun8_2001/medicine.html

35. http://www.buteyko.co.nz/asthma/triggers/allergens.cfm

36. Παπαδημητρίου Κ.: Ειδική Παθολογική Ανατομική. Σελ. 36-7, Εκδ. Λίτσας, 1990

37. Jackson B.: Early Intervention in asthma. Clinical Vision Ltd, The Old Chapel Harwell, UK, 1995

38. Wills-Karp M., Brandt D., Morrow A.L.: Understanding the origin of asthma and its relationship to breastfeeding. Adv. Exp. Med. Biol. 554: 171-191 (2004)

39. Oddy W.H., Sherriff J.L., de Klerk N.H., Kendall G.E., Sly P.D., Beilin L.J.: The relation of breastfeeding and body mass index to asthma and atopy in children: a pro­spective cohort study to age 6 years. Am. J. Public Health 94: 1531-1537 (2004)

40. Κουτούση Χ., Κωστούδη Σ., Μυρωνίδου-Τζουβελέκη Μ.: Η σημασία του θηλασμού και η ιστορία του θηλάστρου. Παιδιατρική Βορείου Ελλάδος 17: 19-30 (2005)

41. Falliers C.J.: Emergent Asthma, Endogenous, Exo­genous, or Iatrogenous. Chest 127: 427-429 (2005)

42. http://www.aap.org/pubed/ZZZM6H8SA7C.htm?&sub_cat=1

43. http://www.livoniafamily.com/ptedu/Files/Asthma.htm

44. http://www.doctorsecrets.com/your-medicine/symptoms-of-an-asthma-attack.html

45. Covar RA., Macomber BA., Szefler SJ.: Medications as asthma triggers. Immunol. Allergy Clin. North Am. 25: 169-190 (2005)

46. Rosenow E.: Drug-induced pulmonary disease, Dis­ease-a-month 40: 258-310 (1994)

47. Babu K.S., Marshall B.G.: Drug-induced airway diseases. Clin. Chest Med. 25: 113-122 (2004)

48. Cottin V., Cordier J.F.: Iatrogenic drug-induced bronchospasm, cough, and bronchiolitis. Etiologic and physiopathologic aspects. Rev. Mal. Respir. 13: 339-360 (1996)

49. Meeker D.P., Wiedemann H.P.: Drug-induced bronchospasm. Clin. Chest Med. 11: 163-175 (1990)

50. Clark G., Camus P., Frey J.G.: Drug-induced lung disease in general practice, Rev. Med. Suisse 8: 1549-1554 (2005)

51. http://www.buteyko.co.nz/asthma/triggers/medications.cfm

52. http://www.asthma.org.uk/about/factsheet09.php

53. Dow L.: Asthma in older people, Clin. Exp Allergy 28 (Suppl 5): 195-205 (1998)

54. Leuppi J.D., Schnyder P., Hartmann K., Reinhart W.H., Kuhn M.: Drug-induced bronchospasm: analysis of 187 spontaneously reported cases. Respiration 68: 345-351 (2001)

55. Greek National Formulary. Pp. 497-515, Athens, 2003

56. Reid J., Rubin P., Whiting B.: Κλινική Φαρμακολογία. Σελ. 119-23, 210-5, εκδ. Παρισιάνου, Αθήνα, 1999

57. Babu S., Salvi S.: Aspirin and Asthma. Chest 118: 1470-1476 (2000)

58. Ben Noun L.: Drug-induced respiratory disorders: incidence, prevention and management. Drug Saf. 23: 143-164 (2000)

59. http://www.allergycapital.com.au/PAGES/GPaspirin.html

60. Knox A.J.: Aspirin induced asthma, How prevalent is aspirin induced asthma? Thorax 57: 565-566 (2002)

61. Kasper L., Sladek K., Duplaga M., Bochenek G., Liebhart J., Gladysz U., Malolepszy J., Szczeklik A.: Prevalence of asthma with aspirin hypersensitivity in the adult population of Poland. Allergy 58: 1064 (2003)

62. Jenkins C, Costello J, Hodge L. Systematic review of prevalence of aspirin induced asthma and its implications for clinical practice. BMJ 328: 434 (2004)

63. Dekker J.W., Nizankowska E., Schmitz-Schumann M., Pile K., Bochenek G., Dyczek A., Cookson W.O., Szczeklik A.: Aspirin-induced asthma and HLA-DRB1 and HLA-DPB1 genotypes. Clin. Exp. Allergy 27: 574-577 (1997)

64. Schiappoli M., Gani F., Frati F., Marcucci F., Senna G.: Asthma and aspirin. Recent Prog. Med. 94: 79-87 (2003)

65. Hamad A.M., Sutcliffe A.M., Knox A.J.: Aspirin-induced asthma: clinical aspects, pathogenesis and management. Drugs 64: 2417-2432 (2004)

66. Shi J., Misso N.L.A., Duffy D.L., Bradley B., Beard R., Thompson P.J., Kedda M.A.: Cyclooxygenase-1 gene polymorphisms in patients with different asthma phenotypes and atopy. Eur. Respir. J. 26: 249-256 (2005)

67. Κωστούδη Σ., Μυρωνίδου-Τζουβελέκη Μ.: Ανεπιθύ-μητες ενέργειες στο αναπνευστικό μετά από χορήγηση φαρμάκων. Γαληνός 48: 23-44 (2006)

68. Vally H., Taylor M.L., Thompson P.J.: The prevalence of aspirin intolerant asthma (AIA) in Australian asthmatic patients. Thorax 57: 569-574 (2002)

69. Mastalerz L., Setkowicz M., Sanak M., Szczeklik A.: Hypersensitivity to aspirin: common eicosanoid alterations in urticaria and asthma. J. Allergy Clin. Immu­nol. 113: 771-775 (2004)

70. http://www.nationalasthma.org.au/html/management/infopapers/health_professionals/3004.asp

71. Greek National Formulary. Pp. 167-168, Athens, 2003

72. Walsh G.M.: Novel therapies for asthma advances and problems. Curr. Pharm. Des. 11: 3027-3038 (2005)

73. Lee D.K.C., Haggart K., Robb F.M., LipworthB.J.: Montelukast protects against nasal lysine-aspirin chal­lenge in patients with aspirin-induced asthma. Eur. Res­pir. 24: 226-230 (2004)

74. Morwood K., Gillis D., Smith W., Kette F.: Aspirin-sensitive asthma. Intern. Med. J. 35: 240-246 (2005)

75. Szczeklik A., Stevenson D.: Aspirin-induced asthma: Advances in pathogenesis, diagnosis, and management, J. Allergy Clin. Immunol. 111: 913-921 (2003)

76. Pedersen S.: Comparing inhaled glucocorticoster­oids. Allergy 54 (Supplement 49): 42-50 (1999)

77. Rothe T., Achermann R., Hug J., Karrer W.: Incom­plete aspirin desensitization in an aspirin-sensitive asth­matic. Int. Arch. Allergy Immunol. 109: 298-300 (1996)

78. http://en.wikipedia.org/wiki/Samter’s_triad

79. http://www.respiratoryreviews.com/jun03/rr_jun03_aspirin.html

80. Priel I.E.: Fatal asthma: where did we go wrong? Med. Law 12: 351-361 (1993)

81. Mascia K., Haselkorn T., Deniz Y., Miller D., Bleecker E., Borish L.: Aspirin sensitivity and severity of asthma: Evidence for irreversible airway obstruction in patients with severe or difficult-to-treat asthma. J. Allergy Clin. Immunol. 116: 970-975 (2005)

82. Kauffman R.E., Lieh-Lai M.: Ibuprofen and increased morbidity in children with asthma: fact or fiction? Paediatr Drugs 6: 267-272 (2004)

83. http://www.ohiohealth.com/healthreference/reference/1C585058-A294-402A-9E26D98A538863C4.htm?category=questions

84. Im Hof V.I.: Beta blockers and bronchial asthma, Schweiz Rundsch Med Prax 84: 319-320 (1995)

85. Greek National Formulary. Pp. 98-104, Athens, 2003

86. http://www.medic8.com/healthguide/articles/betablockers.html

87. http://www.pharmacytimes.com/article.cfm?ID=68

88. Kozlova L.I., Aisanov Z.R., Chuchalin A.G.: What is the danger of long-term application of beta blockers in patients with ischemic heart disease and concomitant chronic obstructive pulmonary disease? Ter. Arkh. 77: 18-23 (2005)

89. Lawrence D.S., Sahay J.N., Chatterjee S.S., Cruick­shank J.M.: Asthma and beta-blockers. Eur. J. Clin. Pharmacoll. 22: 501-509 (1982)

90. Stewart W.C., Garrison P.M.: Beta-blocker-induced complications and the patient with glaucoma. Newer treatments to help reduce systemic adverse events. Arch. Inter. Med. 158: 221-226 (1998)

91. Stewart W.C., Castelli W.P.: Systemic side effects of topical beta-adrenergic blockers. Clin. Cardiol. 19: 691-697 (1996)

92. http://www.healthypages.net/news.asp?newsid=2524

93. Sica D.A.: Current concepts of pharmacotherapy in hypertension–ophthalmically administered beta blockers and their cardiopulmonary effects. J. Clin. Hypertens. (Greenwich) 3: 175-178 (2001)

94. Fraunfelder F.T., Meyer S.M.: Systemic reactions to ophthalmic drug preparations, Med. Toxicol. Adverse Drug Exp. 2: 287-293 (1987)

95. Lama P: Systemic adverse effects of beta-adrenergic blockers: an evidence-based assessment. Am. J. Oph­thalmol. 134: 749-760 (2002)

96. Greek National Formulary. Pp. 546-557, Athens, 2003

97. Banks J.R., Kagey-Sobotka A., Lichtenstein L.M., Eggleston P.A.: Spontaneous histamine release after exposure to hyperosmolar solutions. J. Allergy Clin. Im­munol. 78: 51-57 (1986)

98. Thomas M., Peedicavil J., Koshi T., Korah I.: Adverse reactions to radiocontrast media in an Indian population. Br. J. Radiol. 72: 648-652 (1999)

99. Morcos S.K., Thomsen H.S.: Adverse reactions to iodinated contrast media. Eur. Radiol. 11: 1267-1275 (2001)

100. Wittbrodt E.T., Spinler S.A.: Prevention of anaphy­lactoid reactions in high-risk patients receiving radio­graphic contrast media, Ann. Pharmacothe.r 28: 236-241 (1994)

101. Lang D.M., Alpern M.B., Visintainer P.F., Smith S.T.: Increased risk for anaphylactoid reaction from contrast media in patients on beta-adrenergic blockers or with asthma. Ann. Intern. Med. 115: 270-276 (1991)

102. Mortele K.J., Oliva M.R., Ondategui S., Ros P.R., Silverman S.G.: Universal use of nonionic iodinated con­trast medium for CT: evaluation of safety in a large urban teaching hospital. AJR Am. Roentgenol. 184: 31-34 (2005)

103. Morcos S.K.: Review article: Effects of radiographic contrast media on the lung. Br. J. Radiol. 76: 290-295 (2003)

104. Laude E.A., Emery C.J., Suvarna S.K., Morcos S.K.: The effect of antihistamine, endothelin antagonist and corticosteroid prophylaxis on contrast media induced bronchospasm. Br. J. Radiol. 72: 1058-1063 (1999)

105. Greek National Formulary. Pp. 669-672, Athens, 2003

106. http://www.tga.gov.au/docs/html/aadrbltn/aadr0006.htm

107. Wierda J.M.K.H.: Towards the ideal neuromuscular blocking agent. Research group of experimental Anes­thesiology and Clinical Pharmacology, University of Groningen. Ρ. 41,43,45, The Netherlands, 1990

108. Greek National Formulary. Pp. 663-667, Athens, 2003

109. Katzung BG.: Basic and Clinical Pharmacology. Pp. 434-439, Mc Graw Hill, International Edition, 2004

110. Γεωργιάδης Μ.: Περιεγχειρητική αντιμετώπιση αλλεργικού ασθενούς, Θέματα Αναισθησιολογίας και Εντατικής Ιατρικής 25: 101-112 (2002)

111. Μυρωνίδου-Τζουβελέκη Μ.: Μυοχαλαρωτικά φάρμακα, Επιστημονική Επετηρίδα του Τμήματος Ιατρικής 201: 119-144 (1993)

112. Mertes P.M., Laxenaire M.C.: Anaphylactic and anaphylactoid reactions occurring during anaesthesia in France. Seventh epidemiologic survey (January 2001-December 2002). Ann. Fr. Anesth. Reanim. 23: 1133-1143 (2004)

113. Hughes S., Calverley P.M.: Heroin inhalation and asthma. BMJ 297: 1511-1512 (1988)

114. Levine M., Iliescu M.E., Margellos-Anast H., Estar­ziau M., Ansell D.A.: The effects of cocaine and heroin use on intubation rates and hospital utilization in patients with acute asthma exacerbations. Chest 128: 1951-1957 (2005)

115. Tashkin D.P.: Airway effects of marijuana, cocaine, and other inhaled illicit agent. Curr. Opin. Pulm. Med. 7: 43-61 (2001)

116. Leikin J.B., Morris R.W., Warren M., Erickson T.: Trends in a decade of drug abuse presentation to an inner city ED. Am. J. Emerg. Med. 19: 37-39 (2001)

117. Rome L.A., Lippmann M.L., Dalsey W.C., Taggart P., Pomerantz S.: Prevalence of cocaine use and its impact on asthma exacerbation in an urban population. Chest 117: 1324-1329 (2000)

118. Tashkin D.P., Kleerup E.C., Koyal S.N., Marques J.A., Goldman M.D.: Acute effects of inhaled and i.v. cocaine on airway dynamics. Chest 110: 904-910 (1996)

119. Levenson T., Greenberger P.A., Donoghue E.R., Lifschultz B.D.: Asthma deaths confounded by substance abuse. An assessment of fatal asthma. Chest 110: 604-610 (1996)

120. Averbach M., Casey K.K., Frank E.: Near-fatal status asthmaticus induced by nasal insufflation of co­caine. South Med. J. 89: 340-341 (1996)

121. Tasjkin D.P., Simmons M.S., Chang P., Coulson A.H.: Effects of smoked substance abuse on nonspecific airway hyperresponsiveness. Am. Rev. Respir. Dis. 147: 97-103 (1993)

122. Krantz A.J., Hershow R.C., Prachand N., Hayden D.M., Franklin C., Hryhorczuk D.O.: Heroin insufflation as a trigger for patients with life-threatening asthma. Chest 123: 510-517 (2003)